INT58459

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1993
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 13
Total Number 15
Disease Relevance 6.46
Pain Relevance 4.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL2) extracellular region (IL2) cell adhesion (IL2)
cell-cell signaling (IL2)
Anatomy Link Frequency
lymphocytes 8
T cell 6
PBMC 4
lymph node 2
IL2 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 180 100.00 Very High Very High Very High
noradrenaline 3 99.98 Very High Very High Very High
Multiple sclerosis 30 99.94 Very High Very High Very High
dexamethasone 9 99.62 Very High Very High Very High
antagonist 66 99.16 Very High Very High Very High
Enkephalin 1 96.64 Very High Very High Very High
anesthesia 5 96.48 Very High Very High Very High
Inflammation 193 94.40 High High
headache 17 94.32 High High
aspirin 1 94.28 High High
Disease Link Frequency Relevance Heat
Multiple Sclerosis 15 100.00 Very High Very High Very High
Demyelinating Disease 22 99.94 Very High Very High Very High
Paralysis 1 99.60 Very High Very High Very High
Disease 38 98.78 Very High Very High Very High
Asthma 316 98.28 Very High Very High Very High
Anaerobic Bacterial Infections 2 97.92 Very High Very High Very High
Viral Meningitis 10 96.44 Very High Very High Very High
Sprains And Strains 3 94.72 High High
Headache 13 94.64 High High
INFLAMMATION 198 94.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The immunomodulatory capacity of these compounds was evaluated by determining the interleukin-2 (IL-2) release in mitogen activated PBMC.
Spec (determining) Negative_regulation (determining) of Localization (release) of IL-2 in PBMC
1) Confidence 0.41 Published 2004 Journal Life Sci. Section Abstract Doc Link 15102522 Disease Relevance 0.09 Pain Relevance 0.53
The immunomodulatory capacity of these compounds was evaluated by determining the interleukin-2 (IL-2) release in mitogen activated PBMC.
Spec (determining) Negative_regulation (determining) of Localization (release) of interleukin-2 in PBMC
2) Confidence 0.41 Published 2004 Journal Life Sci. Section Abstract Doc Link 15102522 Disease Relevance 0.09 Pain Relevance 0.53
In contrast, mitogen-induced lymphocyte proliferation and IL-2 secretion are not depressed.
Neg (not) Negative_regulation (depressed) of Localization (secretion) of IL-2 in lymphocyte
3) Confidence 0.36 Published 1997 Journal Int. J. Immunopharmacol. Section Abstract Doc Link 9278182 Disease Relevance 0.10 Pain Relevance 0.22
We have also shown that tetanus toxoid (TT) specific CD4+ T cell clones, with a known cytokine production profile, were sensitive to the inhibitory effects of thiopental and exhibited decreased proliferation to TT as well as decreased secretion of IL-2.
Negative_regulation (decreased) of Localization (secretion) of IL-2 in T cell associated with anaerobic bacterial infections and cytokine
4) Confidence 0.36 Published 1997 Journal Int. J. Immunopharmacol. Section Abstract Doc Link 9278182 Disease Relevance 0.10 Pain Relevance 0.21
To evaluate systemic T cell activation and reactivity against putative autoantigens in multiple sclerosis (MS), numbers of interleukin-2 (IL-2) secreting cells were determined in peripheral blood of 32 patients with MS, 7 patients with acute aseptic meningitis (AM) and 12 patients with tension headache (TH).
Negative_regulation (numbers) of Localization (secreting) of IL-2 in T cell associated with multiple sclerosis, headache and viral meningitis
5) Confidence 0.23 Published 1993 Journal J. Neurol. Sci. Section Abstract Doc Link 8289087 Disease Relevance 1.10 Pain Relevance 0.58
There was no correlation between numbers of IL-2 secreting cells in MS patients and clinical variables, including exacerbation versus remission, disability and duration of disease.
Negative_regulation (numbers) of Localization (secreting) of IL-2 associated with multiple sclerosis and disease
6) Confidence 0.23 Published 1993 Journal J. Neurol. Sci. Section Abstract Doc Link 8289087 Disease Relevance 1.55 Pain Relevance 0.77
The ability of AEA to suppress T-cell proliferation was also substantiated by its ability to markedly inhibit IL-2 release from activated T-lymphocytes, again in a CB2R-mediated manner.
Negative_regulation (inhibit) of Localization (release) of IL-2 in T-lymphocytes
7) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2809084 Disease Relevance 0.40 Pain Relevance 0.26
This result is consistent with a previous report, where inhibition of IL-2 release from phytohemagglutinin-stimulated PBMCs was found to be mediated by CB2R [23].
Negative_regulation (inhibition) of Localization (release) of IL-2
8) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2809084 Disease Relevance 0.27 Pain Relevance 0.25
A similar suppression of NKCC and IL-2 secretion was observed in the three groups.
Negative_regulation (suppression) of Localization (secretion) of IL-2
9) Confidence 0.09 Published 2008 Journal J Opioid Manag Section Body Doc Link 18444445 Disease Relevance 0 Pain Relevance 0
In vitro, the cysteinyl-leukotriene receptor antagonist pranlukast can concentration-dependently inhibit the release of Th2 cytokines (IL-3, IL-4, GM-CSF), but not of the Th1 cytokine IL-2, from mite allergen-stimulated PBMCs from asthmatic patients [37].
Negative_regulation (inhibit) of Localization (release) of IL-2 associated with asthma, antagonist and cytokine
10) Confidence 0.07 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 0.74 Pain Relevance 0.42
Clinical signs of disease such as abnormal gait and limb paralysis, proliferation and IL-2 secretion of lymph node cells, as well as cell-dependent antibody production in EAE mice were reduced by andrographolide treatment [68].
Negative_regulation (reduced) of Localization (secretion) of IL-2 in lymph node associated with multiple sclerosis, disease and paralysis
11) Confidence 0.04 Published 2010 Journal Chin Med Section Body Doc Link PMC2881933 Disease Relevance 1.07 Pain Relevance 0.15
98 nM and inhibited anti-CD3/CD-28-induced secretion of IL-2 in T cells isolated from human peripheral blood lymphocytes with IC50?
Negative_regulation (isolated) of Localization (secretion) of IL-2 in lymphocytes
12) Confidence 0.03 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.29 Pain Relevance 0.09
98 nM and inhibited anti-CD3/CD-28-induced secretion of IL-2 in T cells isolated from human peripheral blood lymphocytes with IC50?
Negative_regulation (/) of Localization (secretion) of IL-2 in lymphocytes
13) Confidence 0.03 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.29 Pain Relevance 0.09
98 nM and inhibited anti-CD3/CD-28-induced secretion of IL-2 in T cells isolated from human peripheral blood lymphocytes with IC50?
Negative_regulation (inhibited) of Localization (secretion) of IL-2 in lymphocytes
14) Confidence 0.03 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.29 Pain Relevance 0.09
Dexamethasone and noradrenaline suppressed secretion of IL-2, IFN alpha, IFN gamma, TNF alpha, IL-1 alpha and IL-1 beta. beta-Endorphin and Leu-Enkephalin had no significant influence on cytokine secretion.
Negative_regulation (suppressed) of Localization (secretion) of IL-2 associated with noradrenaline, enkephalin, dexamethasone and cytokine
15) Confidence 0.03 Published 1997 Journal Eur. J. Cancer Section Abstract Doc Link 9389931 Disease Relevance 0.07 Pain Relevance 0.70

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox